Trial reportPloS one2019
Longitudinal evaluation of visual function and structure for detection of subclinical Ethambutol-induced optic neuropathy.
Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Neuro-ophthalmic complications of tuberculosis and its treatment: a systematic review and meta-analysis.Frontiers in ophthalmology · 2026Pooled it
- Ethambutol optic neuropathy in the extended anti-tubercular therapy regime: A systematic review.Indian journal of ophthalmology · 2023Pooled it
- Longitudinal Observation by Optical Coherence Tomography in Patients Treated with Ethambutol: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Temporal evolution and factors influencing visual function and RNFL thickness in ethambutol-associated optic neuropathy.European journal of medical research · 2025Observational
- Factors affecting visual outcome in patients with toxic optic neuropathy caused by ethambutol.Scientific reports · 2025Article
- Ethambutol-Induced Optic Neuropathy: A Retrospective Study of Incidences and Risk Factors.Cureus · 2025Article
- Identifying predictors of visual improvement in ethambutol optic neuropathy: insights from a 5-year retrospective analysis in a tertiary clinic in Indonesia.International journal of ophthalmology · 2025Article
- Risk factors associated with post-tuberculosis sequelae: a systematic review and meta-analysis.EClinicalMedicine · 2024Article
- Maculopapillary Bundle Degeneration in Optic Neuropathies.Current neurology and neuroscience reports · 2024Review
- Visual Recovery Time in Patients with Ethambutol-induced Toxic Optic Neuropathy.Korean journal of ophthalmology : KJO · 2024Review
- Ethambutol and visual assessment in England: current practice and recommendations.Eye (London, England) · 2024Article
- Article
- Can the long term using of pregabalin in fibromyalgia affect the choroid and retinal nerve fiber layer?Eye (London, England) · 2022Article
- Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy.Indian journal of ophthalmology · 2021Article
- Increasing prevalence of resistance to second-line drugs among multidrug-resistant Mycobacterium tuberculosis isolates in Kuwait.Scientific reports · 2021Article
- Recent advances and future directions on the use of optical coherence tomography in neuro-ophthalmology.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo longitudinally evaluate the visual function and structure of patients taking ethambutol by various modalities and identify useful tests for detection of subclinical ethambutol-induced optic toxicity.
methodsThis retrospective study enrolled 84 patients with newly diagnosed tuberculosis treated with ethambutol. Best-corrected visual acuity (BCVA), color vision, contrast sensitivity, fundus and retinal nerve fiber layer (RNFL) photography, automated visual field (VF) test, and optical coherence tomography (OCT) were performed: prior to starting; every month during administration, and 1 month after stoppage. We longitudinally compared visual function and structure with the baseline and identified the occurrence of subclinical toxicity.
resultsBCVA, color vision, and contrast sensitivity showed no change from the baseline. Mean temporal RNFL thickness was significantly increased at 6 months (p = 0.014). Subclinical toxicity was found in 22 eyes of 14 patients (i.e., 13% of 168 eyes), in the forms of VFI decrease (VF index, 9 eyes of 6 patients), quadrant RNFL thickness increase (5 eyes of 4 patients), and VF pattern defect (12 eyes of 6 patients). 73% of the patients showed recovery to the baseline at 1 month post-stoppage. The risk factors for occurrence of subclinical toxicity were age, cumulative dose, and medication duration.
conclusionMean temporal RNFL thickness increased after administration. The VFI, quadrant RNFL thickness, and VF pattern defect could prove useful in assessment of subclinical toxicity. Medication duration was shown to be a strong risk factor for occurrence of subclinical toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.